^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:belvarafenib (RG6185) (pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

    Excerpt:
    ...- NRAS-mutant Melanoma...
    Trial ID:
    NCT03284502
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

    Excerpt:
    There were two PRs each in patients with NRAS-mutant melanoma (2/9), BRAF-mutant melanoma (2/6) and BRAF-mutant CRC (2/7), respectively….Belvarafenib was well tolerated and exhibited anti-tumor activity in patients with advanced solid tumors harboring RAS or RAF mutations.
    DOI:
    10.1200/JCO.2019.37.15_suppl.3000
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Clin Exp Metastasis
    Title:

    Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model

    Published date:
    02/10/2023
    Excerpt:
    Belvarafenib strongly suppressed melanoma in BRAF V600E mutant A375SM tumor-bearing mice. It also significantly inhibited tumor growth in NRAS mutant SK-MEL-30 and K1735 tumor-bearing mice and synergized to enhance the antitumor activity combined with cobimetinib or atezolizumab.
    DOI:
    10.1007/s10585-023-10198-7